Ryan Cohlhepp - 02 Feb 2026 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Reporting relationship: President and COO, Director
Issuer ticker: BCAX
Reported as of: 02 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Feb 2026, 16:38:05 UTC
Prior SEC filing: 26 Jan 2026
Next SEC filing: 27 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Lara Meisner, Attorney-in-Fact

Key filing fact

Ryan Cohlhepp filed Form 4 for Bicara Therapeutics Inc. (BCAX) on 04 Feb 2026.

Key facts

This page summarizes Ryan Cohlhepp's Form 4 filing for Bicara Therapeutics Inc. (BCAX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Feb 2026, 16:38.

Change

Previous filing in this sequence was filed on 26 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002034665 Primary reporting owner

Cohlhepp Ryan

Relationship: President and COO, Director
Address: BICARA THERAPEUTICS INC., 116 HUNTINGTON AVENUE, SUITE 703, BOSTON
Signature: /s/ Lara Meisner, Attorney-in-Fact
Signature date: 04 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCAX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +300,000
Change %
Price: $0.000000
Shares after: 300,000
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $16.76
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date.